These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35800481)

  • 21. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
    Ader M; Garvey WT; Phillips LS; Nemeroff CB; Gharabawi G; Mahmoud R; Greenspan A; Berry SA; Musselman DL; Morein J; Zhu Y; Mao L; Bergman RN
    J Psychiatr Res; 2008 Oct; 42(13):1076-85. PubMed ID: 18295798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia.
    Amini K; Motallebi MJ; Bakhtiari K; Hajmiri MS; Zamanirafe M; Sharifikia M; Ranjbar A; Keshavarzi A; Mirjalili M; Mehrpooya M
    Hum Psychopharmacol; 2024 Jun; ():e2907. PubMed ID: 38940745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
    Tran PV; Hamilton SH; Kuntz AJ; Potvin JH; Andersen SW; Beasley C; Tollefson GD
    J Clin Psychopharmacol; 1997 Oct; 17(5):407-18. PubMed ID: 9315992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.
    Meltzer HY; Bonaccorso S; Bobo WV; Chen Y; Jayathilake K
    J Clin Psychiatry; 2011 Dec; 72(12):1602-10. PubMed ID: 21813074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
    Bret P; Bonnet F; Bret MC; Jaffré A
    Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
    Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
    J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic risk factor-profile in patients on treatment with second generation antipsychotics.
    Zahan T; Akhter N; Mullick MSI; Dewan ZF
    Bangladesh Med Res Counc Bull; 2015 Dec; 41(3):144-150. PubMed ID: 29870170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.
    Jeste DV; Barak Y; Madhusoodanan S; Grossman F; Gharabawi G
    Am J Geriatr Psychiatry; 2003; 11(6):638-47. PubMed ID: 14609804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.
    de Araújo AA; Ribeiro SB; Dos Santos AC; Lemos TM; Medeiros CA; Guerra GC; de Araújo Júnior RF; Serrano-Blanco A; Rubio-Valera M
    Psychiatr Q; 2016 Jun; 87(2):293-304. PubMed ID: 26220635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
    Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
    J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
    McKee JR; Bodfish JW; Mahorney SL; Heeth WL; Ball MP
    J Clin Psychiatry; 2005 Sep; 66(9):1161-8. PubMed ID: 16187775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
    Arango C; Giráldez M; Merchán-Naranjo J; Baeza I; Castro-Fornieles J; Alda JA; Martínez-Cantarero C; Moreno C; de Andrés P; Cuerda C; de la Serna E; Correll CU; Fraguas D; Parellada M
    J Am Acad Child Adolesc Psychiatry; 2014 Nov; 53(11):1179-90,1190.e1-4. PubMed ID: 25440308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.